期刊文献+

表没食子儿茶素没食子酸酯对心脑血管缺血再灌注损伤保护作用机制的研究进展 被引量:8

Research progress on neuroprotective mechanism of epigallocatechin-3-gallate against cardiovascular and cerebrovascular ischemia-reperfusion injury
原文传递
导出
摘要 表没食子儿茶素没食子酸酯(epigallocatechin-3-gallate,EGCG)是绿茶的主要成分之一。研究表明,EGCG具有抗氧化、预防癌症、抗炎、抗菌等作用。近年来,心脑血管疾病已成为当今世界影响人类健康最显著的疾病,而目前仅有少数神经保护药物能够用于治疗缺血性中风。很多基础研究证实,EGCG对于心脑血管缺血再灌注损伤具有独特的疗效,主要体现在调节氧化应激、抗细胞凋亡、抗炎、激活腺苷受体、降低血脑屏障的通透性及降低基质金属蛋白酶-9(MMP-9)表达等方面。针对EGCG对心脑血管缺血再灌注损伤保护作用机制进行综述,以期能为有效治疗心脑血管缺血性疾病药物的开发提供参考。 Epigallocatechin-3-gaUate (EGCG) is one of the major components in green tea. It has been studied that EGCG possesses anti-oxidative, anticancer, anti-inflammatory, and antibacterial effects. In recent years, cardiovascular and cerebrovascular diseases have been exerting the most significant impact on human health, however, only a few neuroprotective drugs can be used in the treatment of ischemic stroke. Many studies reveal that EGCG has unique therapeutic effect on cardiovascular and cerebrovascular ischemia-reperfusion injury. EGCG mainly exerts its protective effects by regulating oxidative stress, anti-apopsis, anti-inflammation, activation of adenosine receptors, lowering blood-brain barrier permeability, and reducing matrix metalloproteinase-9 expression. This review focuses on the mechanism of action of EGCG in the treatment of cardiovascular and cerebrovascular ischemia-reperfusion injury, in order to provide rationale or the development of effective drugs for ischemic cardiovascular and cerebrovascular diseases.
出处 《中草药》 CAS CSCD 北大核心 2014年第18期2732-2736,共5页 Chinese Traditional and Herbal Drugs
基金 国家自然科学基金资助项目(81274124)
关键词 表没食子儿茶素没食子酸酯 心脑血管 缺血再灌注损伤 抗氧化 抗炎 epigallocatechin-3-gallate cardiovascular and cerebrovascular ischemic reperfusion injury anti-oxidation anti-inflammation
  • 相关文献

参考文献2

二级参考文献88

  • 1Hochegger K, Jansky G L, Solei man A, Wolf AM, Tagwerker A, Seger C et al. Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol2008; 19: 1520-1529.
  • 2Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84: 1492-1499.
  • 3Letavernier E, Bruneval P, Mandet C, Van Huyen JP, Peraldi MN, Hetal I et aL High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007 ; 2: 326-333.
  • 4Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK etal. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34-40.
  • 5Yoshida M, Xia Y. Heat Shock Protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase. J Biol Chem 2003; 278: 36953-36958.
  • 6Fessel WJ. Epidemiology of systemic lupus erythematosus. Rheum Dis Clin North Am 1988; 14: 15-23.
  • 7Le Marchand L. Cancer preventive effects of flavonoids - a review. Biomed Pharmacother2002; 56: 296-301.
  • 8Farabegoli F, Barbi C, Lambertini E, Piva R. (-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect Prey 2007; 31 : 499-504.
  • 9Shankar S, Ganapathy S, Hingorani SR, Srivastava RK. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 2008; 13: 440-452.
  • 10Wolfram S, Raederstorff D, Preller M, Wang Y, Teixeira SR, Riegger C et al. Epigallocatechie gallate supplementation alleviates diabetes in rodents. J IVutr 2006; 136: 2512-2518.

共引文献23

同被引文献138

  • 1孙世利,杨军国,张岚翠,于海宁,沈生荣.儿茶素与金属离子相互作用及其生物学意义[J].细胞生物学杂志,2007,29(2):225-228. 被引量:9
  • 2中华心血管病杂志编辑委员会.不稳定性心绞痛诊断和治疗建议中华医学会心血管病学分会[J].中华心血管病杂志,2000,(6):22-24.
  • 3王忠诚.神经外科学[M].武汉:湖北科学技术出版社,2005.620-621.
  • 4黄群,李彦坡,陈林杰,车科.冠突散囊菌液态发酵过程中黑茶活性成分变化研究[J].食品科学,2007,28(12):231-234. 被引量:22
  • 5Itoh T, Tabuchi M, Mizuguchi N, et al. Neuroprotective effect of(-)-epigallocatechin-3-gallate in rats when administered pre-or post-traumatic brain injury[J]. J Neural Transm, 2013, 120(5):767-783.
  • 6Pardridge W M. Brain Drug Targeting[M]. Cambridge:Cambridge University Press, 1998.
  • 7Baltzley S, Mohammad A, Malkawi A H, et al. Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles[J]. AAPS Pharm Sci Tech, 2014, 15(6):1598-1602.
  • 8Jafarieh O, Md S, Ali M, et al. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting[J]. Drug Dev Ind Pharm, 2015, 41(10):1674-1681.
  • 9Fazil M, Md S, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting[J]. Eur J Pharm Sci, 2012, 47(1):6-15.
  • 10Illum L. Transport of drugs from the nasal cavity to the central nervous system[J]. Eur J Pharm Sci, 2000, 11(1):1-18.

引证文献8

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部